Literature DB >> 18464290

Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB.

Sylvie Monferran1, Nicolas Skuli1, Caroline Delmas1, Gilles Favre1, Jacques Bonnet2, Elizabeth Cohen-Jonathan-Moyal1,2, Christine Toulas1.   

Abstract

Integrins are extracellular matrix receptors involved in tumour invasion and angiogenesis. Although there is evidence that inhibiting integrins might enhance the efficiency of radiotherapy, little is known about the exact mechanisms involved in the integrin-dependent modulation of tumor radiosensitivity. The purpose of this study was to investigate the role of alphavbeta3 and alphavbeta5 integrins in glioblastoma cell radioresistance and overall to decipher the downstream biological pathways. We first demonstrated that silencing alphavbeta3 and alphavbeta5 integrins with specific siRNAs significantly reduced the survival after irradiation of 2 glioblastoma cell lines: U87 and SF763. We then showed that integrin activity and integrin signalling pathways controlled the glioma cell radiosensitivity. This regulation of glioma cell response to ionising radiation was mediated through the integrin-linked kinase, ILK, and the small GTPase, RhoB, by two mechanisms. The first one, independent of ILK, consists in the regulation of the intracellular level of RhoB by alphavbeta3 or alphavbeta5 integrin. The second pathway involved in cell radiosensitivity consists in RhoB activation by ionising radiation through ILK. Furthermore, we demonstrated that the alphavbeta3/alphavbeta5 integrins/ILK/RhoB pathway controlled the glioma cells radiosensitivity by regulating radiation-induced mitotic cell death. This work identifies a new biological pathway controlling glioblastoma cells radioresistance, activated from the membrane through alphavbeta3 and/or alphavbeta5 integrins via ILK and RhoB. Our results are clues that downstream effectors of alphavbeta3 and alphavbeta5 integrins as ILK and RhoB might also be promising candidate targets for improving the efficiency of radiotherapy and thus the clinical outcome of patients with glioblastoma. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18464290     DOI: 10.1002/ijc.23498

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  49 in total

1.  RHOB influences lung adenocarcinoma metastasis and resistance in a host-sensitive manner.

Authors:  Diego Luis-Ravelo; Iker Antón; Carolina Zandueta; Karmele Valencia; María-José Pajares; Jackeline Agorreta; Luis Montuenga; Silvestre Vicent; Ignacio I Wistuba; Javier De Las Rivas; Fernando Lecanda
Journal:  Mol Oncol       Date:  2013-11-12       Impact factor: 6.603

2.  Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel.

Authors:  Anat Eldar-Boock; Keren Miller; Joaquin Sanchis; Ruth Lupu; María J Vicent; Ronit Satchi-Fainaro
Journal:  Biomaterials       Date:  2011-03-04       Impact factor: 12.479

3.  Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.

Authors:  Soléakhéna Ken; Alexandra Deviers; Thomas Filleron; Isabelle Catalaa; Jean-Albert Lotterie; Jonathan Khalifa; Vincent Lubrano; Isabelle Berry; Patrice Péran; Pierre Celsis; Elizabeth Cohen-Jonathan Moyal; Anne Laprie
Journal:  J Neurooncol       Date:  2015-07-19       Impact factor: 4.130

Review 4.  Effects of irradiation on tumor cell survival, invasion and angiogenesis.

Authors:  Odysseas Kargiotis; Aliki Geka; Jasti S Rao; Athanasios P Kyritsis
Journal:  J Neurooncol       Date:  2010-05-07       Impact factor: 4.130

5.  Identification of vitronectin as an extrinsic inducer of cancer stem cell differentiation and tumor formation.

Authors:  Elaine M Hurt; King Chan; Maria Ana Duhagon Serrat; Suneetha B Thomas; Timothy D Veenstra; William L Farrar
Journal:  Stem Cells       Date:  2010-03-31       Impact factor: 6.277

6.  RhoB promotes cancer initiation by protecting keratinocytes from UVB-induced apoptosis but limits tumor aggressiveness.

Authors:  Nicolas Meyer; Alexis Peyret-Lacombe; Bruno Canguilhem; Claire Médale-Giamarchi; Kenza Mamouni; Agnese Cristini; Sylvie Monferran; Laurence Lamant; Thomas Filleron; Anne Pradines; Olivier Sordet; Gilles Favre
Journal:  J Invest Dermatol       Date:  2013-06-21       Impact factor: 8.551

7.  Role of a DNA damage checkpoint pathway in ionizing radiation-induced glioblastoma cell migration and invasion.

Authors:  Issai Vanan; Zhiwan Dong; Elena Tosti; Gregg Warshaw; Marc Symons; Rosamaria Ruggieri
Journal:  Cell Mol Neurobiol       Date:  2012-05-03       Impact factor: 5.046

8.  Anti-angiogenic therapy induces integrin-linked kinase 1 up-regulation in a mouse model of glioblastoma.

Authors:  Chiara Verpelli; Giulio Bertani; Valentina Cea; Monica Patti; Andreas Bikfalvi; Lorenzo Bello; Carlo Sala
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

9.  Critical functions of RhoB in support of glioblastoma tumorigenesis.

Authors:  Yufang Ma; Yuanying Gong; Zhixiang Cheng; Sudan Loganathan; Crystal Kao; Jann N Sarkaria; Ty W Abel; Jialiang Wang
Journal:  Neuro Oncol       Date:  2014-09-12       Impact factor: 12.300

10.  Cisplatin suppresses the growth and proliferation of breast and cervical cancer cell lines by inhibiting integrin β5-mediated glycolysis.

Authors:  Shaojia Wang; Jie Xie; Jiajia Li; Fei Liu; Xiaohua Wu; Ziliang Wang
Journal:  Am J Cancer Res       Date:  2016-05-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.